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ABSTRACT
Smoking is the most well- established cause of chronic 
airflow obstruction (CAO) but particulate air pollution 
and poverty have also been implicated. We regressed 
sex- specific prevalence of CAO from 41 Burden of 
Obstructive Lung Disease study sites against smoking 
prevalence from the same study, the gross national 
income per capita and the local annual mean level 
of ambient particulate matter (PM2.5) using negative 
binomial regression. The prevalence of CAO was not 
independently associated with PM2.5 but was strongly 
associated with smoking and was also associated with 
poverty. Strengthening tobacco control and improved 
understanding of the link between CAO and poverty 
should be prioritised.
INTRODUCTION
The most important cause of chronic airflow 
obstruction (CAO) is tobacco smoking. The Global 
Burden of Disease programme has suggested that 
air pollution is second only to smoking in deter-
mining loss of disability- adjusted life- years due to 
chronic respiratory disease.1 Evidence for this was 
obtained by applying the risk of disease associated 
with air pollution exposure, as estimated from 
various studies, to the known distribution of fine 
particulate matter (PM2.5) across the world.
In this analysis, we investigated the ecological 
association (ie, using aggregated data)2 between 
the prevalence of CAO, as estimated from a large 
multisite study, and levels of ambient PM2.5.
METHODS
The prevalence of CAO and the prevalence of 
smoking were estimated for 41 sites of the Burden 
of Obstructive Lung Disease (BOLD) study (online 
supplemental file for details).3 The level of poverty 
of each site was estimated from the gross national 
income (GNI) per capita at the time of the survey, 
using data from the World Bank.4 Annual mean 
PM2.5 levels (all composition, and dust and sea- salt 
removed (DSSR)) for each site coordinates and a 
10 km radius buffer (site as centre) were obtained 
from a public dataset.5 6
The unit of our analysis was the site, and the 
analysis was stratified by sex (online supplemental 
file for details).
RESULTS
The prevalence of CAO across sites ranged from 
3.5% to 23.2% in men, and from 2% to 19.4% in 
women (table 1). As expected, the prevalence of 
CAO was substantially lower among never smokers 
(online supplemental table S1).
The prevalence of smoking varied from 4.6% to 
84.4% in men and from 0% to 61.3% in women. 
The levels of all composition PM2.5 ranged from 
4 µg/m3 in Reykjavik (Iceland) to 68 µg/m3 in 
Karachi (Pakistan). The GNI varied from $1120 in 
Malawi to $51 250 in Saudi Arabia (table 1).
Lower PM2.5 levels were weakly correlated with a 
higher prevalence of CAO, in both sexes (figure 1A). 
Among never smokers (figure 1B) and when using 
DSSR PM2.5, there was no correlation (figure 1C).
In both sexes, the prevalence of CAO was strongly 
positively associated with smoking and negatively 
associated with GNI. There was no association of 
prevalence of CAO with levels of PM2.5 (all compo-
sition) (table 2). The sensitivity analyses using all 
composition PM2.5 for a 10 km radius buffer and 
using DSSR PM2.5 showed no substantive difference 
from the main analysis (online supplemental tables 
S2–S4).
DISCUSSION
We were unable to show evidence of an ecological 
association between the prevalence of CAO and 
annual mean levels of PM2.5, although we have 
shown clear independent associations with the 
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prevalence of smoking and GNI.
Our findings suggest that PM2.5 is unlikely to have a substan-
tial effect on the prevalence of CAO. We have previously shown 




















































































































































































































































































































































































































































































































































































Figure 1 Relation between prevalence of chronic airflow obstruction 
and annual mean levels of (a) PM2.5 (all composition, μg/m
3) for the 
whole sample, (B) PM2.5 (all composition, μg/m
3) for never smokers and 
(C) PM2.5 (dust and sea- salt removed, μg/m
3) for the whole sample.
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also unlikely to be substantially associated with CAO,7 a conclu-
sion supported by the findings of three large Chinese studies.8–10 
Our findings are compatible with the large European ESCAPE 
project, which showed little evidence of an effect of any pollutant 
on the FEV1/FVC or its change over time.
11
This analysis has several strengths. The aggregate data on prev-
alence of CAO and smoking were taken directly from the BOLD 
study. Spirometry was post- bronchodilator, and its quality was 
assured with a strong training programme and regular review of 
all spirograms in a quality control centre.
All ecological analyses have potential weaknesses. One is the 
temptation to ascribe the associations observed at the site level to 
similar associations at an individual level. In this instance, there 
is independent analysis showing the association of CAO with 
smoking12 and poverty13 at the individual level within the BOLD 
study.
Ecological analyses are also prone to confounding. There 
are strong ecological associations between the prevalence of 
smoking, GNI and PM2.5. The poorer countries have fewer 
smokers, less CAO and greater pollution levels. This probably 
explains the negative association of CAO with PM2.5 in the 
population as a whole, which was not seen for never smokers 
(figure 1B), or with DSSR PM2.5, or in the regression analysis 
adjusted for smoking prevalence and GNI.
Ecological analyses can be misleading if the average expo-
sure in a site does not represent the exposure of those with 
the disease.14 Although there may be differences in pollution 
exposure within each site, these are likely to be small compared 
with the larger variation between sites, which ranged from 4 µg/
m3 in Reykjavik (Iceland) to 68 µg/m3 in Karachi (Pakistan). It 
is unlikely that anyone living in Karachi will have exposure to 
ambient PM2.5 lower than any of those living in Reykjavik. The 
wide variation in income across sites is probably less well repre-
sented by GNI. Using the same estimate of GNI for rural and 
urban areas is likely to lead to more substantial errors than the 
approximations made for PM2.5. Nevertheless, we have found 
an association between poverty and CAO both at the ecological 
and individual levels in the BOLD study,13 and it is likely that the 
imprecision introduced here by using GNI to represent the site 
income has reduced the strength of association with CAO.
These results do not imply that air pollution is not harmful 
to lung growth in utero and during childhood, lung health or 
general health, and we clearly do not address in this study the 
potential of PM2.5 to cause other pathologies or to trigger acute 
exacerbations of disease. We cannot exclude the possibility that 
the toxicology of PM2.5 varies geographically, that a component 
of PM2.5 causes CAO but it is not always present, or that there 
is another pollutant that is highly correlated with PM2.5 in some 
sites that causes CAO. Several researchers have suggested that 
the properties15 or sources16 of particles may also be important 
in determining their effects.
This ecological study shows that, after adjustment for smoking 
and GNI, ambient PM2.5 is unlikely to explain a substan-
tial amount of the prevalence of CAO, while the ecological 
association of smoking with CAO is strong and the association 
of poverty with CAO indicates that this is also likely to play an 
important role in its origins.
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Table 2 Ecological negative binomial regression of chronic airflow obstruction against log(GNI), smoking and log(PM2.5), by sex
Variable
men women
Rate ratio 95% CI P value Rate ratio 95% CI P value
Smoking 4.17 2.40 to 7.26 <0.001 11.3 5.64 to 22.6 <0.001
Log(GNI) 0.90 0.81 to 0.99 0.04 0.83 0.73 to 0.94 0.003
Log(PM2.5) 0.92 0.78 to 1.07 0.28 1.05 0.89 to 1.25 0.55
GNI, gross national income; ; PM2.5, particulate matter <2.5µm aerodynamic diameter.
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